Epigenetic therapies for chemoresensitization of epithelial ovarian cancer

Gynecologic Oncology

Volumn 116, Issue 2, 2010, Pages 195-201

  Matei, Daniela E ^a,b   Nephew, Kenneth P ^a,b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chemosensitization; DNMTI; Epigenetics; HDAC inhibitor; Ovarian cancer; Platinum resistance

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; HISTONE DEACETYLASE INHIBITOR;

CHEMOSENSITIZATION; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION; HUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; EPIGENESIS, GENETIC; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 73949106115     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.09.043     Document Type: Review

References (123)

1. Bukowski R.M., Ozols R.F., and Markman M. The management of recurrent ovarian cancer. Semin. Oncol. 34 2 Suppl 2 (2007) S1-S15
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71
3. Yap T.A., Carden C.P., and Kaye S.B. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat. Rev., Cancer 9 3 (2009) 167-181
4. Sandercock J., Parmar M.K., Torri V., and Qian W. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br. J. Cancer 87 8 (2002) 815-824
5. Liu C.M. Cancer of the ovary. N. Engl. J. Med. 352 12 (2005) 1268-1269
6. Toyota M., and Issa J.P. Epigenetic changes in solid and hematopoietic tumors. Semin. Oncol. 32 (2005) 521-530
7. Jones P.A., and Baylin S.B. The epigenomics of cancer. Cell 128 (2007) 683-686
8. Balch C., Huang T.H., Brown R., and Nephew K.P. The epigenetics of ovarian cancer drug resistance and resensitization. Am. J. Obstet. Gynecol. 191 5 (2004) 1552-1572
9. Barton C.A., Hacker N.F., Clark S.J., and O'Brien P.M. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol. Oncol. 109 1 (2008) 129-139
10. Esteller M. Epigenetics in cancer. N. Engl. J. Med. 358 (2008) 1148-1159
11. Schickel R., Boyerinas B., Park S.M., and Peter M.E. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 27 (2008) 5959-5974
12. Iorio M.V., Visone R., Di Leva G., Donati V., Petrocca F., Casalini P., et al. MicroRNA signatures in human ovarian cancer. Cancer Res. 67 (2007) 8699-8707
13. Bernstein B.E., Meissner A., and Lander E.S. The mammalian epigenome. Cell 128 (2007) 668-669
14. Gama-Sosa M.A., Slagel V.A., Trewyn R.W., Oxenhandler R., Kuo K.C., Gehrke C.W., et al. The 5-methylcytosine content of DNA from human tumors. Nucleic Acids Res. 11 (1983) 6883-6894
15. Ehrlich M. DNA methylation in cancer: too much, but also too little. Oncogene 21 (2002) 5400-5413
16. Qu G., Dubeau L., Narayan A., Yu M., and Ehrlich M. Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. Mut. Res. 423 (1999) 91-101
17. Cheng P., Schmutte C., Cofer K.F., Felix J.C., Yu M.C., and Dubeau L. Alterations in DNA methylation are early, but not initial, events in ovarian tumorigenesis. Br. J. Cancer 75 (1997) 396-402
18. Ehrlich M., Woods C., Yu M., Dubeau L., Yang F., Campan M., et al. Quantitative analysis of association between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors. Oncogene 25 (2006) 2636-2645
19. Pattamadilok J., Huapai N., Rattanatanyong P., Vasurattana A., Triratanachat S., Tresukosol D., et al. LINE-1 hypomethylation level as a potential prognostic factor for epithelial ovarian cancer. Int. J. Gynecol. Cancer 18 (2008) 711-717
20. Widschwendter M., Jiang G., Woods C., Muller H.M., Fiegl H., Goebel G., et al. DNA hypomethylation and ovarian cancer biology. Cancer Res. 64 (2004) 4472-4480
21. Ehrlich M. DNA methylation and cancer-associated genetic instability. Adv. Exp. Med. Biol. 570 (2005) 363-392
22. Illingworth R.S., and Bird A.P. CpG islands - a rough guide. FEBS Lett. 583 (2009) 1713-1720
23. Strathdee G., Vass J.K., Oien K.A., Siddiqui N., Curto-Garcia J., and Brown R. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy. Gynecol. Oncol. 97 (2005) 898-903
24. Czekierdowski A., Czekierdowska S., Wielgos M., Smolen A., Kaminski P., and Kotarski J. The role of CpG islands hypomethylation and abnormal expression of neuronal protein synuclein-gamma (SNCG) in ovarian cancer. Neuro. Endocrinol. Lett. 27 (2006) 381-386
25. Woloszynska-Read A., James S.R., Link P.A., Yu J., Odunsi K., and Karpf A.R. DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer. Cancer Immun. 7 (2007) 21
26. Murphy S.K., Huang Z., Wen Y., Spillman M.A., Whitaker R.S., Simel L.R., et al. Frequent IGF2/H19 domain epigenetic alterations and elevated IGF2 expression in epithelial ovarian cancer. Mol. Cancer Res. 4 (2006) 283-292
27. Litkouhi B., Kwong J., Lo C.M., Smedley III J.G., McClane B.A., Aponte M., et al. Claudin-4 overexpression in epithelial ovarian cancer is associated with hypomethylation and is a potential target for modulation of tight junction barrier function using a C-terminal fragment of Clostridium perfringens enterotoxin. Neoplasia 9 (2007) 304-314
28. Press J.Z., De Luca A., Boyd N., Young S., Troussard A., Ridge Y., et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 8 (2008) 17
29. Strathdee G., Appleton K., Illand M., Millan D.W., Sargent J., Paul J., et al. Primary ovarian carcinomas display multiple methylator phenotypes involving known tumor suppressor genes. Am. J. Pathol. 58 3 (2001) 1121-1127
30. Milde-Langosch K., Ocon E., Becker G., and Loning T. p16/MTS1 inactivation in ovarian carcinomas: high frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. Int. J. Cancer 79 (1998) 61-65
31. Strathdee G., MacKean M.J., Illand M., and Brown R. A role for methylation of the hMLH1 promoter in loss of hMLH1 expression and drug resistance in ovarian cancer. Oncogene 18 (1999) 2335-2341
32. Ibanez de Caceres I., Battagli C., Esteller M., Herman J.G., Dulaimi E., Edelson M.I., et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res. 64 (2004) 6476-6481
33. Sellar G.C., Watt K.P., Rabiasz G.J., Stronach E.A., Li L., Miller E.P., et al. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat. Genet. 34 (2003) 334-337
34. Socha M.J., Said N., Dai Y., Kwong J., Ramalingam P., Trieu V., et al. Aberrant promoter methylation of sparc in ovarian cancer. Neoplasia 11 (2009) 126-135
35. Kikuchi R., Tsuda H., Kozaki K., Kanai Y., Kasamatsu T., Sengoku K., et al. Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer. Cancer Res. 68 (2008) 5067-5075
36. Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K., Hirohashi S., et al. Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer. Cancer Res. 67 (2007) 7095-7710
37. Feng W., Marquez R.T., Lu Z., Liu J., Lu K.H., Issa J.P., et al. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 112 (2008) 1489-1502
38. Cvetkovic D., Pisarcik D., Lee C., Hamilton T.C., and Abdollahi A. Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer. Gynecol. Oncol. 95 (2004) 449-455
39. Pruitt K., Ulku A.S., Frantz K., Rojas R.J., Muniz-Medina V.M., Rangnekar V.M., et al. Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J. Biol. Chem. 280 (2005) 23363-23370
40. Terasawa K., Sagae S., Toyota M., Tsukada K., Ogi K., Satoh A., et al. Epigenetic inactivation of TMS1/ASC in ovarian cancer. Clin. Cancer Res. 10 (2004) 2000-2006
41. Arnold J.M., Cummings M., Purdie D., and Chenevix-Trench G. Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas. Br. J. Cancer 85 (2001) 1351-1358
42. Yuecheng Y., Hongmei L., and Xiaoyan X. Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin. Exp. Metastasis 23 (2006) 65-74
43. Backen A.C., Cole C.L., Lau S.C., Clamp A.R., McVey R., Gallagher J.T., et al. Heparan sulphate synthetic and editing enzymes in ovarian cancer. Br. J. Cancer 96 (2007) 1544-1548
44. Staub J., Chien J., Pan Y., Qian X., Narita K., Aletti G., et al. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance. Oncogene 26 (2007) 4969-4978
45. Potapova A., Hoffman A.M., Godwin A.K., Al-Saleem T., and Cairns P. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer. Cancer Res. 68 (2008) 998-1002
46. Izutsu N., Maesawa C., Shibazaki M., Oikawa H., Shoji T., Sugiyama T., et al. Epigenetic modification is involved in aberrant expression of class III beta-tubulin, TUBB3, in ovarian cancer cells. Int. J. Oncol. 32 (2008) 1227-1235
47. Fiegl H., Windbichler G., Mueller-Holzner E., Goebel G., Lechner M., Jacobs I.J., et al. HOXA11 DNA methylation-a novel prognostic biomarker in ovarian cancer. Int. J. Cancer 123 (2008) 725-729
48. Ahluwalia A., Yan P., Hurteau J.A., Bigsby R.M., Jung S.H., Huang T.H., et al. DNA methylation and ovarian cancer. I. Analysis of CpG island hypermethylation in human ovarian cancer using differential methylation hybridization. Gynecol. Oncol. 82 (2001) 261-268
49. Wei S.H., Chen C.M., Strathdee G., Harnsomburana J., Shyu C.R., Rahmatpanah F., et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin. Cancer Res. 8 (2002) 225-2246
50. Barton C.A., Hacker N.F., Clark S.J., and O'Brien P.M. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol. Oncol. 109 (2008) 129-139
51. Wei S.H., Balch C., Paik H.H., Kim Y.S., Baldwin R.L., Liyanarachchi S., et al. Prognostic DNA methylation biomarkers in ovarian cancer. Clin. Cancer Res. 12 (2006) 2788-2794
52. Watts G.S., Futscher B.W., Holtan N., Degeest K., Domann F.E., and Rose S.L. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med. Genomics 1 (2008) 47
53. Li M., Balch C., Montgomery J.S., Jeong M., Chung J.H., Yan P., Nephew K.P., et al. Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med. Genomics 2 (2009) 34-46
54. Balch C., Montgomery J.S., Paik H.I., Kim S., Kim S., Huang T.H., et al. New anti-cancer strategies: epigenetic therapies and biomarkers. Front. Biosci. 10 (2005 May 1) 1897-1931
55. Ahluwalia A., Hurteau J.A., Bigsby R.M., and Nephew K.P. DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol. Oncol. 82 (2001) 299-304
56. Leu Y.W., Rahmatpanah F., Shi H., Wei S.H., Liu J.C., Yan P.S., et al. Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation. Cancer Res. 63 (2003) 6110-6115
57. Baldwin R.L., Nemeth E., Tran H., Shvartsman H., Cass I., Narod S., et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res. 60 (2000) 5329-5333
58. Hilton J.L., Geisler J.P., Rathe J.A., Hattermann-Zogg M.A., DeYoung B., and Buller R.E. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J. Natl. Cancer Inst. 94 (2002) 1396-1406
59. Dworkin A.M., Spearman A.D., Tseng S.Y., Sweet K., and Toland A.E. Methylation not a frequent "second hit" in tumors with germline BRCA mutations. Fam. Cancer (2009) [Electronic publication ahead of print]
60. Gifford G., Paul J., Vasey P.A., Kaye S.B., and Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin. Cancer Res. 10 (2004) 4420-4426
61. Su H.Y., Lai H.C., Lin Y.W., Chou Y.C., Liu C.Y., and Yu M.H. An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int. J. Cancer 124 (2009) 387-393
62. Graham J.S., Kaye S.B., and Brown R. The promises and pitfalls of epigenetic therapies in solid tumours. Eur. J. Cancer 45 (2009) 1129-1136
63. Bast Jr. R.C., Hennessy B., and Mills G.B. The biology of ovarian cancer: new opportunities for translation. Nat. Rev., Cancer 9 (2009) 415-428
64. LaVoie H.A. Epigenetic control of ovarian function: the emerging role of histone modifications. Mol. Cell. Endocrinol. 243 (2005) 12-18
65. Ozdag H., Teschendorff A.E., Ahmed A.A., Hyland S.J., Blenkiron C., Bobrow L., et al. Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 7 (2006) 90
66. Caslini C., Capo-chichi C.D., Roland I.H., Nicolas E., Yeung A.T., and Xu X.X. Histone modifications silence the GATA transcription factor genes in ovarian cancer. Oncogene 25 (2006) 5446-5461
67. Valls E., Sanchez-Molina S., and Martinez-Balbas M.A. Role of histone modifications in marking and activating genes through mitosis. J. Biol. Chem. 280 (2005) 42592-42600
68. Richon V.M., Sandhoff T.W., Rifkind R.A., and Marks P.A. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 10014-10019
69. Chan M.W., Huang Y.W., Hartman-Frey C., Kuo C.T., Deatherage D., Qin H., et al. Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia 10 (2008) 908-919
70. Abbosh P.H., Montgomery J.S., Starkey J.A., Novotny M., Zuhowski E.G., Egorin M.J., et al. Dominant-negative histone H3 lysine 27 mutant derepresses silenced tumor suppressor genes and reverses the drug-resistant phenotype in cancer cells. Cancer Res. 66 (2006) 5582-5591
71. Wei Y., Xia W., Zhang Z., Liu J., Wang H., Adsay N.V., et al. Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol. Carcinog. Mol. Carcinog. 47 (2008) 701-706
72. Lyko F., and Brown R. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J. Natl. Cancer Inst. 97 (2005) 1498-1506
73. Plumb J.A., Strathdee G., Sludden J., Kaye S.B., and Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res. 60 21 (2000) 6039-6044
74. Li Y., Hu W., Shen D.Y., Kavanagh J.J., and Fu S. Azacitidine enhances sensitivity of platinum-resistant ovarian cancer cells to carboplatin through induction of apoptosis. Am. J. Obstet. Gynecol. 200(2) 177 (2009) e1-9
75. Gomyo Y., Sasaki J., Branch C., Roth J.A., and Mukhopadhyay T. 5-aza-2′-deoxycytidine upregulates caspase-9 expression cooperating with p53-induced apoptosis in human lung cancer cells. Oncogene 23 40 (2004) 6779-6787
76. Frost P., Abbruzzese J.L., Hunt B., Lee D., and Ellis M. Synergistic cytotoxicity using 2′-deoxy-5-azacytidine and cisplatin or 4-hydroperoxycyclophosphamide with human tumor cells. Cancer Res. 50 15 (1990) 4572-4577
77. Balch C., Yan P., Craft T., Young S., Skalnik D.G., Huang T.H., et al. Antimitogenic and chemosensitizing effects of the methylation inhibitor zebularine in ovarian cancer. Mol. Cancer Ther. 4 10 (2005) 1505-1514
78. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev., Cancer 6 (2006) 38-51
79. Qian X., LaRochelle W.J., Ara G., Wu F., Petersen K.D., Thougaard A., et al. Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies. Mol. Cancer Ther. 5 (2006) 2086-2095
80. Yang Y.T., Balch C., Kulp S., Mand M.R., Nephew K.P., and Chen C.S. A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer. Neoplasia 11 (2009) 552-563
81. Karpf A.R., and Jones D.A. Reactivating the expression of methylation silenced genes in human cancer. Oncogene 21 (2002) 5496-5503
82. Steele N., Finn P., Brown R., and Plumb J.A. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo. Br. J. Cancer 100 (2009) 758-7631
83. Kim I.K., Li C.C., Young H.A., Lee J.H., Kim H.S., Pardhasaradhi K., et al. Apoptosis of L1210 leukemia cells induced by 3-deazaadenosine analogs: differential expression of c-myc, NF-kappa B and molecular events. J. Biomed. Sci. 4 (1997) 83-90
84. Issa J.P., Gharibyan V., Cortes J., Jelinek J., Morris G., Verstovsek S., et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J. Clin. Oncol. 23 (2005) 3948-3956
85. Kantarjian H.M. Treatment of myelodysplastic syndrome: questions raised by the azacitidine experience. J. Clin. Oncol. 20 (2002) 2415-2416
86. Kornblith A.B., Herndon II J.E., Silverman L.R., Demakos E.P., Odchimar-Reissig R., Holland J.F., et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J. Clin. Oncol. 20 (2002) 2441-2452
87. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20 (2002) 2429-2440
88. Silverman L.R., McKenzie D.R., Peterson B.L., Holland J.F., Backstrom J.T., Beach C.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J. Clin. Oncol. 24 (2006) 3895-3903
89. Kuykendall J.R. 5-azacytidine and decitabine monotherapies of myelodysplastic disorders. Ann. Pharmacother. 39 (2005) 1700-1709
90. de Vos D., and van Overveld W. Decitabine: a historical review of the development of an epigenetic drug. Ann. Hematol. 84 Suppl 13 (2005) 3-8
91. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106 (2006) 1794-1803
92. Attadia V. Effects of 5-aza-2′-deoxycytidine on differentiation and oncogene expression in the human monoblastic leukemia cell line U-937. Leukemia 7 Suppl 1 (1993) 9-16
93. Pinto A., Attadia V., Fusco A., Ferrara F., Spada O.A., and Di Fiore P.P. 5-Aza-2′-deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64 (1984) 922-929
94. Jones P.A., and Taylor S.M. Cellular differentiation, cytidine analogs and DNA methylation. Cell 20 (1980) 85-93
95. Willemze R., Archimbaud E., and Muus P. Preliminary results with 5-aza-2′-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group. Leukemia 7 Suppl 1 (1993) 49-50
96. Kantarjian H.M., and Issa J.P. Decitabine dosing schedules. Semin. Hematol. 42 (2005) S17-S22
97. O'Brien S.M., F R.-K., Giles S., et al. Decitabine low dose schedule in myelodysplastic syndrome, comparison of three different dose schedules. J. Clin. Oncol. Suppl 16 (2005)
98. Wijermans P., Lubbert M., Verhoef G., Bosly A., Ravoet C., Andre M., et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 18 (2000) 956-962
99. Samlowski W.E., Leachman S.A., Wade M., Cassidy P., Porter-Gill P., Busby L., et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J. Clin. Oncol. 23 (2005) 3897-3905
100. Aparicio A., Eads C.A., Leong L.A., Laird P.W., Newman E.M., Synold T.W., et al. Phase I trial of continuous infusion 5-aza-2′-deoxycytidine. Cancer Chemother. Pharmacol. 51 (2003) 231-239
101. Aparicio A., and Weber J.S. Review of the clinical experience with 5-azacytidine and 5-aza-2′-deoxycytidine in solid tumors. Curr. Opin. Investig. Drugs 3 (2002) 627-633
102. Schrump D.S., Fischette M.R., Nguyen D.M., Zhao M., Li X., Kunst T.F., et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin. Cancer Res. 12 (2006) 5777-5785
103. Manetta A., Blessing J.A., and Look K.Y. A phase II study of fazarabine in patients with advanced ovarian cancer. A Gynecologic Oncology Group study. Am. J. Clin. Oncol. 18 (1995) 156-157
104. Appleton K., Mackay H.J., Judson I., Plumb J.A., McCormick C., Strathdee G., et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J. Clin. Oncol. 25 (2007) 4603-4609
105. Brown R., Plumb J.A., McCormick C., Lee C., Barrett S., Tang A., et al. Pharmacodynamic effects in patients treated with 6 hour infusion of the demethylating agent 5-aza-2′deoxycytidine (decitabine). EORTC, Suppl. Clin. Cancer Res. 11 23 (December 1, 2005)
106. Fang F, Balch C, Schilder S, Breen T, Zhang S, Shen C, et al. A phase I and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Am Assoc Cancer Res in press.
107. Weisenberger D.J., Campan M., Long T.I., Kim M., Woods C., Fiala E., et al. Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res. 33 (2005) 6823-6836
108. Bast R.C., Iyer R.B., Hu W., Kavanagh J., Coleman R.L., Levenback C., et al. A phase IIa study of a sequential regimen using azacitidine to reverse platinum resistance to carboplatin in patients with platinum resistant or refractory epithelial ovarian cancer. J. Clin. Oncol. 26 (2008) (May 20 suppl; abstr 3500) 2008
109. Camphausen K., and Tofilon P.J. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J. Clin. Oncol. 25 (2007) 4051-4056
110. Lin R.J., Nagy L., Inoue S., Shao W., Miller Jr. W.H., and Evans R.M. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391 (1998) 811-814
111. Vigushin D.M., Ali S., Pace P.E., Mirsaidi N., Ito K., Adcock I., et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 7 (2001) 971-976
112. Carducci M.A., Gilbert J., Bowling M.K., Noe D., Eisenberger M.A., Sinibaldi V., et al. A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin. Cancer Res. 7 (2001) 3047-3055
113. Fouladi M., Furman W.L., Chin T., Freeman III B.B., Dudkin L., Stewart C.F., et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report. J. Clin. Oncol. 24 (2006) 3678-3685
114. Klimek V.M., Fircanis S., Maslak P., Guernah I., Baum M., Wu N., et al. Tolerability, pharmacodynamics, and pharmacokinetics studies of depsipeptide (romidepsin) in patients with acute myelogenous leukemia or advanced myelodysplastic syndromes. Clin. Cancer Res. 14 (2008) 826-832
115. Kelly W.K., O'Connor O.A., Krug L.M., Chiao J.H., Heaney M., Curley T., et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23 (2005) 3923-3931
116. O'Connor O.A., Heaney M.L., Schwartz L., Richardson S., Willim R., MacGregor-Cortelli B., et al. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 24 (2006) 166-173
117. Modesitt S.C., Sill M., Hoffman J.S., and Bender D.P. A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol. Oncol. 109 (2008) 182-186
118. Plumb J.A., Finn P.W., Williams R.J., Bandara M.J., Romero M.R., Watkins C.J., et al. Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101. Mol. Cancer Ther. 2 (2003) 721-728
119. Steele N.L., Plumb J.A., Vidal L., Tjornelund J., Knoblauch P., Rasmussen A., et al. A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors. Clin. Cancer Res. 14 (2008) 804-810
120. Venturelli S., Armeanu S., Pathil A., Hsieh C.J., Weiss T.S., Vonthein R., et al. Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular carcinoma. Cancer 109 (2007) 2132-2141
121. Dalgard C.L., Van Quill K.R., and O'Brien J.M. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma. Clin. Cancer Res. 14 (2008) 3113-3123
122. Fiskus W., Wang Y., Joshi R., Rao R., Yang Y., Chen J., et al. Cotreatment with vorinostat enhances activity of MK-0457 (VX-680) against acute and chronic myelogenous leukemia cells. Clin. Cancer Res. 14 (2008) 6106-6115
123. Dasmahapatra G., Yerram N., Dai Y., Dent P., and Grant S. Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation. Clin. Cancer Res. 13 (2007) 4280-4290